David N. Neubauer, MD
Assistant Professor, Department of Psychiatry
Associate Director, Johns Hopkins Sleep Disorders Center
Johns Hopkins Bayview Medical Center
Gary S. Richardson, MD
Senior Research Scientist
Sleep Research and Disorders Center
Henry Ford Hospital
Physicians and Physician Assistants: 1 hour
Nurses: 1 contact hour/0.5 pharmacology contact hours
Nurse Practitioners: 1 contact hour/0.5 pharmacology contact hours Medium
Insomnia, which is experienced in over 30% of the adult population at some point in time, is a condition that significantly affects quality of life. It is also closely linked to comorbidities; it has been recently recognized that there is a significant overlap between insomnia and multiple medical problems. Insomnia is independently associated with worsening health and quality of life to almost the same extent as chronic medical conditions such as heart failure and depression. When insomnia is effectively treated, quality of life and functioning often improve.
Primary care providers play a vital role in health care, and they act as pivotal advocates and educators for patients. Practical strategies that outline how to evaluate and manage patients with insomnia can be extremely useful for these busy practitioners and will help them improve patient care and relieve some of the public health burden imposed by chronic insomnia.
. Target Audience
This program has been developed for primary care physicians, nurse practitioners, physician assistants, and nurses who treat patients with insomnia.
Upon completion of this educational activity, the participant should be able to:
Discuss insomnia as a medical condition and the ways to recognize patients who may be at risk for insomnia
Explore the impact of insomnia on the patient, including medical and psychiatric conditions, quality of life, and work and social functioning
Outline appropriate behavioral and pharmacologic strategies for management of insomnia
Summarize the efficacy and safety data on pharmacologic agents approved for the treatment of insomnia
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
David N. Neubauer, MD, discloses that he has been a member of the speakers bureau and has served on advisory committees for sanofi-aventis U.S. and Takeda Pharmaceuticals North America, Inc. He has served on advisory committees for Neurocrine Biosciences, Inc., and Pfizer Inc.
Gary S. Richardson, MD, discloses that he has been a member of the speakers bureau, has served on advisory committees, and has provided product consultation services for sanofi-aventis U.S. and Takeda Pharmaceuticals North America, Inc. He has provided product consultation services and has served on advisory committees for Jazz Pharmaceuticals, Inc.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Education: American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s) TM.
Nurse Continuing Education: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. is also an approved provider through the Board of Nursing in CA, #CEP12070. AKH Inc. designates this educational activity for 1 contact hour which includes 0.5 pharmacology contact hour.
Nurse Practitioner Continuing Education: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number 030803. AKH Inc. designates this educational activity for 1 contact hour which includes 0.5 pharmacology contact hour.
Participants must successfully complete the post-test with a grade of 70% or higher and submit an evaluation to receive credit. One retake is allowed.
Commercial Support Statements
Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Complete the short survey and click on "done."
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. This activity will require approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button. Complete the short survey and click on "done."
Instructions for completing and submitting the post-test and program evaluation are provided on the post-test screen. A credit certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Takeda Pharmaceuticals North America, Inc. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.